{"commentary":{"count":300,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":189,"youtube":57,"podcast":51,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04660344\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMvigor011","nct_id":"NCT04660344","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imvigor011-nct04660344. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"IMvigor011","arms":[{"description":"Atezolizumab will be administered intravenously (IV) at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.","label":"Arm A: Atezolizumab","type":"EXPERIMENTAL"},{"description":"Placebo will be administered IV on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor. Following the primary analysis, participants randomized to the comparator arm might discontinue placebo and may receive treatment outside the study at the investigator's discretion.","label":"Arm B: Placebo","type":"PLACEBO_COMPARATOR"},{"description":"Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.","label":"Arm C: Surveillance Follow-Up","type":"EXPERIMENTAL"}],"collaborators":["Natera, Inc."],"completion_date":{"date":"2026-10-01","type":"ESTIMATED"},"conditions":["Muscle-invasive Bladder Cancer"],"enrollment":{"count":761,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Placebo","type":"OTHER"},{"name":"Signatera","type":"DEVICE"}],"last_update":"2026-09-28","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"INV-assessed Disease-free Survival (DFS)","timeFrame":"From randomization to the first occurrence of a DFS event (Up to 48.2 months)"}],"references":[{"citation":"Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Urun Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE; IMvigor011 Investigators. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025 Dec 18;393(24):2395-2408. doi: 10.1056/NEJMoa2511885. Epub 2025 Oct 20.","pmid":"41124204","type":"DERIVED"},{"citation":"Jackson-Spence F, Toms C, O'Mahony LF, Choy J, Flanders L, Szabados B, Powles T. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 2023 Mar;19(7):509-515. doi: 10.2217/fon-2022-0868. Epub 2023 Apr 21.","pmid":"37082935","type":"DERIVED"}],"start_date":{"date":"2021-05-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","url":"https://clinicaltrials.gov/study/NCT04660344"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imvigor011-nct04660344"}